Recent breakthroughs in multimodal Artificial Intelligence (AI) are fundamentally reshaping the landscape of cancer research, ushering in an era of unprecedented precision in diagnosis and personalized treatment. By intelligently integrating diverse data types—from medical imaging and genomic profiles to clinical notes and real-world patient data—these advanced AI systems offer a holistic and nuanced understanding of [...]
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central theme at the recent Quarter Century Update conference, where leading experts like Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, illuminated how AI is [...]
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late 2025, an established force, fundamentally reshaping drug development and operational workflows. This shift is not merely incremental but a comprehensive revolution, accelerating Research & [...]
The S&P 500 has staged a remarkable rebound, soaring to unprecedented highs in late 2025 following a period of significant sell-off earlier in the year. This resurgence, driven by a powerful confluence of artificial intelligence advancements, robust corporate earnings, and strategic monetary policy adjustments, signals a dynamic shift in
Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile.
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older.
In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca (lurbinectedin) and Roche's (SIX: ROG, OTCQX: RHHBY) Tecentriq (atezolizumab), along with its subcutaneous formulation Tecentriq Hybreza. This landmark decision sanctions
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented ability to design synthetic proteins for genome editing that not only match but significantly outperform their naturally occurring counterparts. This pivotal development, highlighted by recent research, signals a [...]
